AI Engines For more Details: Perplexity Kagi Labs You
Anxiolytic Effects: Ipsapirone has been studied for its anxiolytic properties, meaning it may help reduce symptoms of anxiety. It is believed to work by modulating serotonin levels in the brain, which can affect mood and anxiety levels.
Antidepressant Effects: Like other serotonin receptor agonists, ipsapirone has been investigated for its potential antidepressant effects. By modulating serotonin signaling, it may help alleviate symptoms of depression in some individuals.
Side Effects: Common side effects associated with ipsapirone use may include dizziness, drowsiness, headache, nausea, and gastrointestinal disturbances. These side effects are typically mild and transient.
Cardiovascular Effects: Ipsapirone may cause changes in heart rate and blood pressure in some individuals. It is important for individuals with cardiovascular conditions to use ipsapirone cautiously and under medical supervision.
Interactions: Ipsapirone may interact with other medications, particularly those that affect serotonin levels in the brain, such as selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs). Combining ipsapirone with these medications may increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by changes in mental status, autonomic dysfunction, and neuromuscular abnormalities.
Withdrawal: Abrupt discontinuation of ipsapirone after long-term use may lead to withdrawal symptoms such as anxiety, insomnia, agitation, and flu-like symptoms. It is recommended to taper off the medication gradually under medical supervision to minimize withdrawal effects.
Liver Function: Ipsapirone may affect liver function, so individuals with pre-existing liver conditions should use it with caution and under medical supervision.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.4 | 0.3 | 10.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 1.8 | 0.72 |
| Allergies | 5.2 | 2.8 | 0.86 |
| Allergy to milk products | 1.6 | 1.6 | 0 |
| Alopecia (Hair Loss) | 1.1 | 1.1 | |
| Alzheimer's disease | 5.8 | 5.1 | 0.14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 0.8 | 2.75 |
| Ankylosing spondylitis | 3.9 | 0.9 | 3.33 |
| Anorexia Nervosa | 1.3 | 2.2 | -0.69 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 4.4 | 3.2 | 0.38 |
| Atherosclerosis | 1.6 | 1.7 | -0.06 |
| Atrial fibrillation | 2.8 | 2.3 | 0.22 |
| Autism | 8.1 | 7.2 | 0.13 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 1.8 | -1 |
| Carcinoma | 4.4 | 2.3 | 0.91 |
| Celiac Disease | 1.8 | 3.1 | -0.72 |
| Cerebral Palsy | 1.8 | 1 | 0.8 |
| Chronic Fatigue Syndrome | 3.8 | 4.1 | -0.08 |
| Chronic Kidney Disease | 3.9 | 1.7 | 1.29 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.4 | -0.17 |
| Chronic Urticaria (Hives) | 1.6 | 1.1 | 0.45 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1 | 0.5 |
| Cognitive Function | 2.2 | 1.6 | 0.38 |
| Colorectal Cancer | 6.1 | 2.4 | 1.54 |
| Constipation | 1.1 | 0.7 | 0.57 |
| Coronary artery disease | 2 | 1.9 | 0.05 |
| COVID-19 | 7.9 | 8.5 | -0.08 |
| Crohn's Disease | 7.1 | 4.5 | 0.58 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0.8 | 1.6 | -1 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.9 | 1.1 | 0.73 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 8.6 | 7.1 | 0.21 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 1.4 | 0.43 |
| Endometriosis | 2.8 | 1.3 | 1.15 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.4 | 2.2 | 0.55 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.7 | 1.1 | 1.45 |
| Functional constipation / chronic idiopathic constipation | 3.6 | 3.1 | 0.16 |
| gallstone disease (gsd) | 3 | 1.6 | 0.88 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.8 | 0.75 |
| Generalized anxiety disorder | 2.9 | 1.6 | 0.81 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.4 | 0.7 | 2.43 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.6 | 1.7 | -1.83 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.1 | 1.4 | 1.21 |
| Heart Failure | 2.9 | 1.6 | 0.81 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.3 | 0.3 | 3.33 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.6 | 0.17 |
| hyperglycemia | 1.9 | 2.2 | -0.16 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4 | 3.9 | 0.03 |
| Hypothyroidism | 0.5 | 0.7 | -0.4 |
| Hypoxia | 3.4 | 0.3 | 10.33 |
| IgA nephropathy (IgAN) | 1.6 | 3 | -0.88 |
| Inflammatory Bowel Disease | 7.5 | 6.7 | 0.12 |
| Insomnia | 1.6 | 2.9 | -0.81 |
| Intelligence | 0.8 | 0.3 | 1.67 |
| Intracranial aneurysms | 1.1 | 0.3 | 2.67 |
| Irritable Bowel Syndrome | 7.1 | 4.5 | 0.58 |
| ischemic stroke | 2 | 1.7 | 0.18 |
| Liver Cirrhosis | 7 | 5 | 0.4 |
| Long COVID | 5.8 | 5.7 | 0.02 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.6 | 1.3 | 0.23 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.3 | 3 |
| ME/CFS with IBS | 0.5 | 1.7 | -2.4 |
| ME/CFS without IBS | 1.8 | 1.8 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.2 | 1 | 0.2 |
| Metabolic Syndrome | 7.6 | 6.9 | 0.1 |
| Mood Disorders | 8.9 | 5.7 | 0.56 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 6.3 | 3.8 | 0.66 |
| Multiple system atrophy (MSA) | 1.7 | 0.4 | 3.25 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 1.2 | 2 | -0.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.7 | 3.7 | 0.27 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.2 | 7.5 | 0.36 |
| obsessive-compulsive disorder | 3.7 | 3.4 | 0.09 |
| Osteoarthritis | 2.1 | 1.4 | 0.5 |
| Osteoporosis | 2.2 | 1.9 | 0.16 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 7.1 | 4.7 | 0.51 |
| Polycystic ovary syndrome | 4.4 | 2.8 | 0.57 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.2 | 1.7 | 0.29 |
| Psoriasis | 3.2 | 2.4 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.6 | 3.5 | 0.89 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 5.2 | 2.7 | 0.93 |
| scoliosis | 0.2 | 0.3 | -0.5 |
| Sjögren syndrome | 2.7 | 2.5 | 0.08 |
| Sleep Apnea | 1.3 | 1.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.3 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.1 | 15 |
| Stress / posttraumatic stress disorder | 3.3 | 3.1 | 0.06 |
| Systemic Lupus Erythematosus | 3.9 | 1.3 | 2 |
| Tic Disorder | 0.8 | 1.4 | -0.75 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 3.6 | 2.7 | 0.33 |
| Type 2 Diabetes | 7.8 | 6 | 0.3 |
| Ulcerative colitis | 4.6 | 5.5 | -0.2 |
| Unhealthy Ageing | 3.6 | 2.2 | 0.64 |
| Vitiligo | 1.5 | 1.4 | 0.07 |
